Last reviewed · How we verify
Estradiol withdrawal
Estradiol withdrawal is a Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved. Also known as: Leuprolide Acetate; Lupron.
At a glance
| Generic name | Estradiol withdrawal |
|---|---|
| Also known as | Leuprolide Acetate; Lupron |
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer (PHASE2)
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. (PHASE1, PHASE2)
- Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age (EARLY_PHASE1)
- A Prospective Multicenter Observational Real-world Study of Retained Products of Conception
- Roll-over Study to Allow Continued Access to Ribociclib (PHASE4)
- HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer (PHASE1)
- A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy (PHASE2)
- The Role of Hormones in Postpartum Mood Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estradiol withdrawal CI brief — competitive landscape report
- Estradiol withdrawal updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI
Frequently asked questions about Estradiol withdrawal
What is Estradiol withdrawal?
Estradiol withdrawal is a Small molecule drug developed by Brigham and Women's Hospital.
Who makes Estradiol withdrawal?
Estradiol withdrawal is developed and marketed by Brigham and Women's Hospital (see full Brigham and Women's Hospital pipeline at /company/brigham-and-women-s-hospital).
Is Estradiol withdrawal also known as anything else?
Estradiol withdrawal is also known as Leuprolide Acetate; Lupron.
What development phase is Estradiol withdrawal in?
Estradiol withdrawal is FDA-approved (marketed).
Related
- Manufacturer: Brigham and Women's Hospital — full pipeline
- Also known as: Leuprolide Acetate; Lupron
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing